EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • RET fusion • ALK fusion • ALK mutation • RET mutation • ROS1 fusion • EGFR positive • NTRK fusion

Avastin (bevacizumab) • etoposide IV • utidelone IV (UTD1)

Analysis of Acquired Fusion Mutations in EGFR-TKIs-Resistant Patients with Advanced Lung Cancer. (PubMed, J Coll Physicians Surg Pak)

One patient with acquired fusion gene mutations developed small-cell lung cancer transformation after ALK-TKIs resistance. Key Words: Lung cancer, ALK fusion, RET fusion, ROS1 fusion, EGFR-TKIs-resistance, Targeted therapy.

2 days ago

Journal

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • RET fusion • ALK fusion • RET mutation • ROS1 fusion

Ensartinib Combined with Radiotherapy for the Treatment of Advanced Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring TPM3-ALK Fusion: A Case Report (PubMed, Zhongguo Fei Ai Za Zhi)

The progression-free survival (PFS) exceeded 32 months, with no significant treatment-related adverse events observed. This study investigates the feasibility of combining targeted therapy with local radiotherapy, guided by genetic testing, to offer novel treatment strategies for patients with advanced primary pulmonary EIMS..

3 days ago

Journal

ALK (Anaplastic lymphoma kinase) • TPM3 (Tropomyosin 3)

ALK fusion

Ensacove (ensartinib)

CCTG BR34: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC (clinicaltrials.gov)

P2, N=301, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026

3 days ago

Trial completion date

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)

EGFR mutation • ALK fusion

cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)

Diagnostic Utility of Expression Imbalance in Idylla GeneFusion Assay for Non-Small Cell Lung Cancer. (PubMed, J Mol Diagn)

One case showed an NOL10::ALK out-of-frame fusion with negative ALK immunohistochemistry and equivocal ALK FISH results. Because the expression imbalance method can detect novel fusions, we recommend its implementation with confirmation testing.

6 days ago

Journal

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • STRN (Striatin) • SQSTM1 (Sequestosome 1) • ERC1 (ELKS/RAB6-Interacting/CAST Family Member 1)

RET fusion • ALK fusion • ROS1 fusion • ALK negative

Idylla™ GeneFusion Assay

TianjinCIH: A Single-center, Phase II Clinical Study of Sacituzumab Govitecan Combined With Toripalimab as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC (clinicaltrials.gov)

P2, N=38, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

7 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR negative

Loqtorzi (toripalimab-tpzi) • Trodelvy (sacituzumab govitecan-hziy)

CA209-9XC: 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC (clinicaltrials.gov)

P=N/A, N=80, Completed, The Netherlands Cancer Institute | Recruiting --> Completed | Trial completion date: Dec 2024 --> Jan 2026

7 days ago

Trial completion • Trial completion date • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)

EGFR wild-type • ALK fusion

Opdivo (nivolumab)

The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy. (PubMed, Int J Mol Sci)

The increase in HER3 expression induced by osimertinib treatment was associated with increased payload release in PC-9 cells. Our results indicate that HER3 dynamics, as well as baseline HER3 expression, modulate payload release from HER3-DXd and support combination strategies to potentiate the antitumor activity of HER3-DXd.

8 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)

EGFR mutation • ALK fusion • ROS1 fusion • ERBB3 positive

Tagrisso (osimertinib) • patritumab deruxtecan (U3-1402)

Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing. (PubMed, Genes (Basel))

Our real-world data confirm the feasibility and clinical value of routine NGS testing for NSCLC. The findings highlight specific genomic patterns in this population and demonstrate that smoking status should not preclude comprehensive molecular testing for canonical drivers.

8 days ago

Journal • Next-generation sequencing

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)

EGFR mutation • KRAS G12C • ALK fusion • KRAS G12

Oncomine Focus Assay

Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report. (PubMed, NPJ Precis Oncol)

After two years of therapy, the child has sustained partial tumor regression on MRI and no new neurological symptoms. We conclude that comprehensive multi-omics analyses are required for correct molecular diagnosis in childhood CNS tumors and can radically impact patient outcome by identifying molecular targets for precision treatment.

8 days ago

Journal

ALK (Anaplastic lymphoma kinase) • SNRNP70 (Small Nuclear Ribonucleoprotein U1 Subunit 70)

ALK fusion

Lorbrena (lorlatinib)